Avisi Technologies, a Redwood City, CA-based ophthalmic medical device company, has raised $10.7 million in a Series A funding round led by MedVenture Partners.
The round also saw participation from Sherpa Healthcare Partners, SNBL-Gemseki, SBI US Gateway Fund, Golden Seeds, OneOneFive, Good Growth Capital, Accanto Partners, Life Sciences Greenhouse Investment, and Quaker Capital Investments.
Read More:Profound Raises $96M in Series C Funding
The company plans to use the funding to support its key SAPPHIRE clinical trial, approved by the FDA in 2025, and to continue developing Avisi’s pipeline of new treatments for all stages of glaucoma.
Avisi Technologies, Inc., a company developing innovative eye-care devices, is conducting the SAPPHIRE Trial to test the safety and effectiveness of VisiPlate®, a new glaucoma device designed to lower eye pressure by improving fluid outflow.
“Glaucoma still places a heavy burden on patients and healthcare systems,” said Justin Fukuyama. “The VisiPlate® device fills an important need in patient care, and we are excited to work with Avisi Technologies to bring this new treatment to patients.”
The VisiPlate® device has many tiny channels to keep fluid flowing and reduce the chance of blockage or repeat procedures. It is made from very thin, body-safe materials to avoid common problems seen with other glaucoma treatments. VisiPlate® has been studied previously in the VITA Trial, with long-term results shared at the 2026 American Glaucoma Society Annual Meeting. The SAPPHIRE trial is now enrolling patients at multiple sites across the U.S.
“Avisi Technologies’ advanced materials and design address key needs for glaucoma patients,” said Darren Cai, PhD, MBA, Managing Partner at Sherpa Healthcare Partners. “VisiPlate’s thin, multi-channel design could change how glaucoma is treated, help keep eye pressure healthy, and improve results for patients with few options.”
About Avisi
Avisi Technologies was founded in 2017 by CEO Rui Jing Jiang through the University of Pennsylvania Y-Prize program, aiming to use new nanotechnologies to prevent vision loss. Combining materials science and ophthalmology, the VisiPlate technology was developed. Early support from the President’s Innovation Prize, NSF SBIR grants, and MedTech Innovator helped Avisi grow quickly.
Read More:Astelia Raises $35M in Funding
